⌕
Ligand Pharmaceuticals · LGND · Nasdaq
Tenet 40 · Weak
Compare
$308.79−2.37%At closeTenet 40 · Weak
$308.79−7.48 (−2.37%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

Ligand Pharmaceuticals (LGND) Stock

Ligand Pharmaceuticals (LGND) closed at $308.79 on Nov 13, 2026; its Tenet Score is 40 of 100 against 313 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

7 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$308.79
Nov 13, 2026
Market cap
$6.2B
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
119.8×
price ÷ earnings
52-week range
175.89 – 326.63
low → high · as of close, Nov 13, 2026
Tenet Score
40/100
Weak · 313 Healthcare peers

Industry: Drugs

Ligand Pharmaceuticals, Inc. scores 40/100. Weak. Strongest on growth, value is the soft spot, trading at 120× earnings versus 313 Healthcare peers.

Tenet Score · vs sector

n=313
40/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
12
Quality
63
Health
16
Growth
70

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueFQualityCHealthFGrowthBMomentumB
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
6.4×
price to book value
P/S
24.3×
price to fiscal 2025 sales
ROE
5%
return on equity
Operating margin
15.3%
fiscal 2025, before interest and tax
Net margin
20.3%
of revenue kept
Current ratio
1.22
current assets to liabilities
Net debt / EBITDA
11.4×
leverage, net of cash
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Ligand Pharmaceuticals, Inc.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are…

Composite computed Nov 13, 2026 · peer basis: Healthcare (n=313) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 123 US ETFs · top wrappers by weightSee all ETFs holding LGND →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Ligand Pharmaceuticals in?

Ligand Pharmaceuticals is in the Healthcare sector and the Drugs industry.

What is Ligand Pharmaceuticals' Tenet Score?

Ligand Pharmaceuticals' Tenet Score is 40 out of 100, ranked against 313 Healthcare peers as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.